Theresa Perrin
Self-Directed Investor & Trader, Former Hospice Nurse
Novo Nordisk's post-earnings selloff is completely unwarranted: it beat and raised yet trades at pre-GLP-1 multiples, making this a final shakeout and a dip-buying opportunity. Upgrades should come in and the stock should rebound quickly. The drop came after Novo reported early to avoid competing with Eli Lilly's results and someone dumped massive puts on the stock seconds before the release. x.com x.com x.comÂ
Oral Wegovy removes one of the biggest barriers to GLP-1 adoption, yet investors are still sleeping on Novo Nordisk even though prescription data already show the launch going very well. Per @agingroy, Ozempic and Mounjaro generated $71 billion in 2025, more than OpenAI and Anthropic's combined $29 billion, and only about 2% of the 800 million eligible patients can currently access them. x.comÂ
Novo Nordisk's Wegovy pill is pharma's holy grail and is expanding the obesity market. Its first quarter after launch was stellar, with about 1 million new patients in three months per @TTRAmyloid. Per Novo's CEO, about 35% of pill users are men versus roughly 25% on injections, and 80% of pill starters never tried a GLP-1 before. The 30-minute fasting rule is no real obstacle, especially as the pill sharply cuts hunger, and data so far show better efficacy beats convenience. x.com x.com x.com … Show more
Novo Nordisk's management showed too little action against near-term problems, leaving the case in real doubt for the first time. A 5-10-year recovery plan clashes with the semaglutide patent expiring within that window, already lost in Canada, India and Turkey, while Eli Lilly poses real threats. Pipeline work in blood/endocrine, liver and cardiovascular is exciting and diversifying would be a game changer, and NovoCare is a positive, but the clock is running and management is uninspiring. … Show more
Novo Nordisk could run with healthcare stocks as tech sells off, helped by the midterm health trend of the last 20 years. The market seems to be looking for value in health and pharma. Novo's $11.8 billion in free cash flow and major buybacks at these levels should eventually lift its depressed price once investors realize Novo and Eli Lilly can both do well in oral GLP-1s, where Novo leads. Novo might have found a bottom. x.comÂ
Novo Nordisk is showing accumulation at a key inflection, with price testing major ascending trendline support near $46.60 as buyers step in. The immediate target is a gap fill at $49-50. Catalysts add potential: oral Wegovy has launched in Germany, China accepted Wegovy, the Phase 3 STEP Young pediatric obesity trial succeeded, an FDA decision on CagriSema is expected in Q4 2026, and a multi-billion DKK buyback is ongoing. x.comÂ
Eli Lilly has the market momentum over Novo Nordisk in GLP-1 drugs. Lilly's Zepbound sold $4B in Q1 against $2.7B for Novo's Wegovy, and Novo's lawsuit over GLP-1 advertising looks defensive. Lilly's direct-to-consumer head start and manufacturing scale appear durable. A GLP-1 market heading to $100B by 2030 remains the most structurally attractive healthcare trade. x.comÂ
Novo Nordisk is one of the best opportunities in the market and a safe haven in an AI-driven market, crushed while its long-term growth story is rebuilt. It trades at 9x earnings with a 4.64% dividend yield, controls about 80% of the GLP-1 weight-loss pill market and plans to scale oral GLP-1 capacity 10x by 2030. Revenue growth is expected to return to double digits in 2027, and it has partnered with Anthropic on drug discovery. It would need a 110% rally to regain its 200-week average. x.comÂ
Novo Nordisk stands to gain from Medicare access starting July 1, 2026, which could let millions of patients get Wegovy, including the new oral pill, for $50 a month. Novo leads on the convenient oral peptide pill while Lilly leads overall with tirzepatide, and Hims now partners with Novo and has stopped pushing most compounded versions. The weekly chart shows an inverse head-and-shoulders breakout. x.comÂ
Novo Nordisk carries too much legal drama to invest in, with lawsuits piling up. The latest, per @AIStockSavvy, is Viatris suing Novo over a patent dispute on generic Wegovy. x.comÂ
Novo Nordisk trades at its lowest valuation ever, about 7x earnings, in the same year it launched one of the most in-demand oral medications in the world. Competition from Eli Lilly is a real headwind, but even if Novo's oral market share fell to 50% it should do fine, and an expected 1-3% earnings drop next year hardly justifies 7x. Novo should still be competing at a similar scale in seven years. x.com x.com x.com x.com x.comÂ